Hereditary angioedema: Epidemiology, management, and role of icatibant

Biologics: Targets and Therapy

Volumn 7, Issue 1, 2013, Pages 103-113

  Ghazi, Aasia ^a   Andrew Grant, J ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Bradykinin; C1 inhibitor; Hereditary angioedema; Icatibant

Indexed keywords

CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; PLACEBO; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; C1 INHIBITOR GENE; CLINICAL FEATURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INJECTION SITE REACTION; LABORATORY TEST; LARYNX EDEMA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PREVALENCE; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE;

EID: 84877113122     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S27566     Document Type: Review

References (67)

1. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417-2429.
2. Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213-217.
3. Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114(1):3-9.
4. Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med. 1996; 334:1666-1667.
5. Quincke H. Concerning the acute localized edema of the skin. Monatsh Prakt Derm. 1882;1:129-131. German.
6. Osler W: Hereditary angioneurotic edema. Am J Med Sci. 1888;95(4): 362-367.
7. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C' 1-esterase. Am J Med. 1963;35:37-44.
8. Dreskin S. Urticaria and angioedema. In: Goldman L, Schafer AI, editors. Cecil Medicine, 24th ed. Philadelphia, PA: Saunders Elsevier; 2011:chap 260.
9. Talavera A, Larraona JL, Ramos JL, et al. Hereditary angioedema: an infrequent cause of abdominal pain with ascites. Am J Gastroenterol. 1995;90:471-474.
10. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(Suppl 3):S51-S131.
11. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84:580-593.
12. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 2000;106(6):1147-1154.
13. Davis AE 3rd. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol. 1988;6:595-628.
14. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am. 2006;26:709-724.
15. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs and course. Am J Med. 2006;119:267-274.
16. Sofia S, Casali A, Bolondi L. Sonographic findings in abdominal hereditary angioedema. J Clin Ultrasound. 1999;27:537-540.
17. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75:349-354.
18. Borum ML, Howard DE. Hereditary angioedema: complex symptoms can make diagnosis difficult. Postgrad Med. 1998;103(251):255-256.
19. Gompels MM, Lock RJ, Abinun M. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379-394.
20. Wagenaar-Bos IG, Drouet C, Aygören-Pursun E, et al. Functional C1-Inhibitor diagnostics in hereditary angioedema: Assay evaluation and recommendations. J Immunol Methods. 2008;338:14-20.
21. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. 2004;114(3):629-637.
22. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.
23. Cicardi M, Bork K, Caballero T, et al; HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to the hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147-157.
24. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513-522.
25. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821-827. e14.
26. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363: 523-531.
27. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6):523-529.
28. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808.
29. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71(4):206-215.
30. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6(1):22.
31. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 2009;15:69-78.
32. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3(3): 311-317.
33. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347(8):621-622.
34. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109(8):1057-1063.
35. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119(6):1497-1503.
36. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102(3): 769-773.
37. Wirth K, Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102(3): 774-777.
38. Félétou M, Martin CA, Molimard M, et al. In vitro effects of HOE 140 in human bronchial and vascular tissue. Eur J Pharmacol. 1995; 274(1-3):57-64.
39. Deeks ED. Icatibant. Drugs. 2010;70(1):73-81.
40. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency CHMP assessment report for Firazyr®. 11-17-2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessm ent_report/human/000899/WC500022970.pdf. Accessed April 5, 2013.
41. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new Bradykinin-receptor antagonist, in hereditary angioedema. N Eng J Med. 2010;363:532-541.
42. 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529-537.
43. Advisory Committee Meeting Briefing Package. Firazyr® (Icatibant). Cambridge, MA: Shire Human Genetic Therapies, Inc; 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria ls/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM260022.pdf. Accessed April 4, 2013.
44. Sharma JN. Cardiovascular activities of the bradykinin system. ScientificWorldJournal. 2008;8:384-393.
45. Sharma JN. Hypertension and the bradykinin system. Curr Hypertens Rep. 2009;11(3):178-181.
46. Shire Human Genetic Therapies, Inc. A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema. In Clinical Trials gov. Last verified: February 2013. Available from http://clinicaltrials.gov/show/NCT01386658. NLM identifier: NCT01386658. Accessed April 9, 2013.
47. Toscani M, Riedl M. Meeting the challenges and burdens associated with hereditary angioedema. Manag Care. 2011;20(9):44-51.
48. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407-414.
49. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010; 104(4):314-320.
50. Alejandro Malbrán, Werner Aberer, William Lumry, et al. Patient Satisfaction with Icatibant During Open-Label Treatment of Hereditary Angioedema Attacks in the FAST-1 and FAST-2 Phase III Trials. Poster presented at EAACI 2011, Istanbul, Turkey. Available from: http://www.postersessiononline.com/173580348_eu/congresos/30eaaci/aula/p oster_42561.pdf. Accessed April 9, 2013.
51. Bowen T. Hereditary angioedema: beyond international consensus - circa December 2010. The Canadian Society of Allergy and Clinical Immunology Dr David McCourtie Lecture. Allergy Asthma Clin Immunol. 2011;7(1):1.
52. Floccard B, Hautin E, Bouillet L, Coppere B, Allaouchiche B. An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II. Core Evid. 2012;7:105-114.
53. Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol. 2010;6(1):21.
54. Blankart CR, Stargardt T, Schreyogg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukemia. Pharmacoeconomics. 2011;29(1):63-82.
55. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
56. Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One. 2013;8(2):e53773.
57. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
58. Longhurst H, Cicardi M. Hereditary angioedema. Lancet. 2012; 379(9814):474-481.
59. Bouillet L. Icatibant in hereditary angioedema: news and challenges. Expert Rev Clin Immunol. 2011;7(3):267-272.
60. Bright P, Dempster J, Longhurst H. Successful treatment of acquired C1 inhibitor deficiency with icatibant. Clin Exp Dermatol. 2010;35(5):553-554.
61. Bouillet L. Hereditary angioedema in women. Allergy Asthma Clin Immunol. 2010;6(1):17.
62. Bouillet L, Boccon-Gibod I, Ponard D, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol. 2009;103(5):448.
63. Weller K, Magerl M, Maurer M. Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol. 2011;25(1):119-120.
64. Gallitelli M, Alzetta M. Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Am J Emerg Med. 2012;30(8):1664. e1-e2.
65. Guichon C, Floccard B, Coppéré B, et al. One hypovolaemic shock...two kinin pathway abnormalities. Intensive Care Med. 2011;37(7): 1227-1228.
66. Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med. 2010;56(3):278-282.
67. Vanderbilt University. Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema. In Clinical Trials gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; Last verified: Dec 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01574248. NLM identifier: NCT01574248. Accessed April 4, 2013.